Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04418167
Recruitment Status : Recruiting
First Posted : June 5, 2020
Last Update Posted : December 13, 2021
Information provided by (Responsible Party):
JS InnoPharm, LLC

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : May 17, 2023
Estimated Study Completion Date : November 17, 2023